Determine the necessary mass, volume, or concentration for preparing a solution.
Pavurutamab , CAS No.2250292-39-6
AVAILABLE TO ORDER
Storage
Store at -20°C
Shipped In
Ice chest + Ice pads
224,000+ research products · Triple ISO certified · COA & SDS available for every product · Same-day shipping on in-stock items
Why this grade
for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Storage & shipping
Store at -20°C Ships Ice chest + Ice pads Check lot-specific COA for exact specifications.
Quality documents
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Literature proof
Cited in 0 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
Overview
Pavurutamab (AMG-701) is a bispecific T cell engager molecule that anti- CD3 and anti- B cell maturation antigens ( BCMA ). Pavurutamab has an extended half-life based on Pacanalotamab . The Fc of Pavurutamab is coupled to molecules to improve pharmacokinetic parameters. Pavurutamab has potential applications in immune regulation and multiple myeloma (MM)
In Vitro
Pavurutamab (0-10000 pM; 48 h) induces CD69 + , CD25 + T cell activation and IFNγ, TNFα, IL-2, IL-4, IL-6, IL-10 cytokine secretion . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Pavurutamab (0.02, 0.2 and 2 mg/kg; i.v.; single dose on days 3, 8, 13) reduces tumor volume with time and dose dependent manner in mouse xenograft models. Pavurutamab (0.005, 0.05 and 0.5 mg/kg; i.v.; every 5 days for 6 administrations, lasting for 30 days) reduces tumor volume and increases survival with time and dose dependent manner in NOD/SCID mice transplanted with L-363 multiple myeloma (MM) cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Female NOD/SCID mice transplanted with NCI-H929 MM cells mixed with PBMCs. Dosage: 0.02, 0.2 and 2 mg/kg. Administration: Intravenous injection; single dose on days 3, 8, 13. Result: Reduced tumor volume. Animal Model: NOD/SCID mice orthotopically transplanted with L-363 MM cells. Dosage: 0.005, 0.05 and 0.5 mg/kg. Administration: Intravenous injection; every 5 days for 6 administrations, starting from day 9 and lasting for 30 days. Result: Reduced tumor volume and increased survival.
IC50& Target:B cell maturation antigens, BCMA
Specifications
Biochemical and Physiological Mechanisms
Pavurutamab (AMG-701) is a bispecific T cell engager molecule that anti- CD3 and anti- B cell maturation antigens ( BCMA ). Pavurutamab has an extended half-life based on Pacanalotamab ( HY-P99798 ). The Fc of Pavurutamab is coupled to molecules to improv
Storage
Store at -20°C
Shipped In
Ice chest + Ice pads
This product requires cold chain shipping. Ground and other economy services are not available.
Action Type
INHIBITOR
Documentation
📋 Safety Data Sheet (SDS)
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →✅ Certificate of Analysis (COA)
Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →🔬 Specification Sheet
Full quality attributes and acceptance criteria for this grade.
View spec sheet →Advanced Data
Certificates（CoA,COO,BSE/TSE and Analysis Chart)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:
Solution Calculators
Reviews
Customer Reviews
Remind me later
Products are supplied to verified businesses, institutions, and qualified professionals for research and development use only. Not for use in humans, animals, diagnosis, or therapy.
Copyright © 2023–present Aladdin Scientific Corp. All rights reserved.